# MYTX-011

Source: https://onco.cc/drugs/mytx-011/  
OnCo record `mytx-011` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MYTX-011 is an experimental antibody-drug conjugate from Mythic Therapeutics, in phase 1 trials for non-small cell lung cancer; its current status is not stated.

## Summary

MYTX-011 is an antibody-drug conjugate (cMET-targeted, MMAE payload, DAR 2) from Mythic Therapeutics. An antibody-drug conjugate targeting cMET (MET) carrying MMAE at a drug-to-antibody ratio of 2, engineered on the FateControl platform. Its furthest stage is phase 1, for non-small cell lung cancer. ClinicalTrials.gov registers it in one study linked below. KisMET-01 (NCT05652868) terminated for 'Business decision' (completion Nov 2025); Mythic made an assignment for the benefit of creditors on 21 Nov 2025 and the assets were offered for sale (bid deadline 5 Jan 2026). Buyer not known. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: MYTX-011
- Modality: Antibody-drug conjugate (cMET-targeted, MMAE payload, DAR 2)
- Mechanism: An antibody-drug conjugate targeting cMET (MET) carrying MMAE at a drug-to-antibody ratio of 2, engineered on the FateControl platform.

## Sources

- Mythic Therapeutics: biospace.com: https://www.biospace.com/press-releases/sale-of-intellectual-property-mythic-therapeutics-inc
- Mythic Therapeutics: biospace.com: https://www.biospace.com/press-releases/sale-of-intellectual-property-mythic-therapeutics-inc
- Mythic Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT05652868
- ClinicalTrials.gov: trials of MYTX-011: https://clinicaltrials.gov/search?intr=MYTX-011

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- targets: [MET](https://onco.cc/targets/met/)
- companies: [Mythic Therapeutics](https://onco.cc/companies/mythic-therapeutics/)
- trials: [Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05652868/)

---
JSON: https://onco.cc/api/v1/entities/mytx-011.json